Buscar en
Endocrinología, Diabetes y Nutrición (English ed.)
Toda la web
Inicio Endocrinología, Diabetes y Nutrición (English ed.) Mosaicism in 2 cases of X-linked hypophosphatemia
Journal Information
Vol. 67. Issue 1.
Pages 70-71 (January 2020)
Vol. 67. Issue 1.
Pages 70-71 (January 2020)
Scientific letter
DOI: 10.1016/j.endien.2020.01.001
Full text access
Mosaicism in 2 cases of X-linked hypophosphatemia
Mosaicismo en 2 casos de hipofosfatemia ligada al cromosoma X
José Jesús Brosetaa,
Corresponding author

Corresponding author.
, Luis Carlos López-Romerob, Juan Antonio Cerónc, Santiago Mendizábald, Julio Hernández-Jarasb
a Servei de Nefrologia i Trasplantament Renal, Institut Clínic de Nefrologia i Urologia, Hospital Clínic, Barcelona, Spain
b Servicio de Nefrología, Área Clínica del Riñón y Vías Urinarias, Hospital Universitari i Politècnic La Fe, Valencia, Spain
c Unidad de Genética, Área de Diagnóstico Biomédico, Hospital Universitari i Politècnic La Fe, Valencia, Spain
d Sección de Nefrología Pediátrica, Área de las Enfermedades del Niño, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Article information
Full Text
Download PDF
Tables (1)
Table 1. Laboratory test findings at diagnosis.
Full Text

Although X-linked hypophosphatemia (XLH) is regarded as a rare disease, it is the most common form of the heterogeneous group of hereditary disorders known as hypophosphatemic rickets. The prevalence of HLH is 1:20,000,1 and the origin of the disorder is a mutation of the PHEX gene, located on the short arm of chromosome 22, which encodes for a phosphate-regulating endopeptidase. Hundreds of mutational varieties have been described2 that encode for abnormal PHEX proteins, which lose their function of inhibiting fibroblast growth factor 23. This results in the suppression of the expression of the tubular cell sodium-phosphorus cotransporter, and thus produces a decrease in the tubular reabsorption of phosphate, with hypophosphatemia.3 In addition, fibroblast growth factor 23 suppresses the levels and activity of α-1-hydroxylase, leading to a decrease in the levels of 1,25-dihydroxyvitamin D, the active form of vitamin D.

The disease exhibits a broad phenotypic variability, and its signs and symptoms include: rickets, osteomalacia, short stature, lower limb bowing, craniosynostosis, bone pain, fractures, extraskeletal calcifications, dentinal defects and neurosensory deafness, among other manifestations. Studies have shown XLH to have a significant impact upon the quality of life of these patients, with reduced mobility and functional disability.4,5

The classical treatment of XLH has been based on the oral supplementation of phosphorus and calcitriol. Such treatment is associated with low patient adherence, due to poor gastrointestinal tolerance, and is not without significant adverse effects, such as nephrocalcinosis or secondary hyperparathyroidism.6 However, a new human monoclonal anti-fibroblast growth factor 23 antibody, burosumab, approved by the EMA and the FDA, and already in pediatric compassionate use in Spain, has opened up the possibility of blocking the mechanism of the disease and ensuring normal development in childhood.7 Furthermore, its possible role in adults is currently under study.8

The present letter reports two cases involving mutations not previously reported in the literature.

Clinical case 1

A boy aged two years and 8 months was referred due to bilateral genu varum from the age of 9 months. Until then he had been followed-up on by Traumatology only; there was no other relevant medical history. Blood and urine tests were performed (Table 1), with findings consistent with XLH. Renal ultrasound showed no alterations. A genetic study was thus requested, and treatment with oral phosphorus and calcitriol was started.

Table 1.

Laboratory test findings at diagnosis.

  Case 1  Case 2 
Phosphorus (mg/dl) (3.7–5.6)  2.5  2.4 
TRP (%) (> 82 %)  62.23 %  78 % 
Alkaline phosphatase (IU/l) (35–290)  659  680 
Calcium (mg/dl) (8.5–10.5)  10.1 
PTH (pg/ml) (11.5–78.5)  33.8  84.3 
FGF-23 (kRU/l) (26–110)  210.5  134.1 
25(OH)D (ng/ml) (30–65)  38.7  33.8 
125(OH)2D (pg/ml) (17.9–70)  69.8  57.4 
Phosphaturia (mg/24 h) (400–1000)  1,837  824 
Calciuria (mg/24 h) (0–250)  102  45 
Glycosuria (mg/dl) (< 100)  13  26 
Urinary pH (4.8–7.4)  5.2 

FGF-23: fibroblast growth factor 23; PTH: parathyroid hormone; TRP: tubular reabsorption of phosphate; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)2D: 1,25-hydroxyvitamin D.

The sequencing study of the PHEX gene identified the c.2182C > T; p.Gln728Ter mutation, a stop codon in apparent heterozygosis, despite being located on the X chromosome of a male. The patient was confirmed as having a single X chromosome (karyotype study [46 XY]) and a single allele of the PHEX gene (established using the multiplex ligation-dependent probe amplification [MLPA] method). The genetic study of the mother did not reveal the studied variant of the PHEX gene; the condition was therefore classified as a de novo mutation. To the best of our knowledge, this variant has not been previously reported in the literature. Apparent heterozygosis was identified in DNA from peripheral blood and saliva; it was therefore found in mesoderm and ectoderm, and demonstrated both by next-generation sequencing (NGS) and the Sanger method.

During follow-up, the patient required osteotomy and plaque placement to correct significant lower limb deformities.

Clinical case 2

An 18-year-old woman had been diagnosed with XLH at two years and 7 months of age (Table 1). At that time it was already known that her mother, also affected by the disorder, was of extremely short stature and had marked lower limb bowing. In contrast, the patient suffered scant morbidity, with subsequent normal weight, height and skeletal development.

A genetic study was performed using the MLPA technique. The karyotype was characterized by a majority mosaic trisomy 47XXX (22/25 metaphases) as compared to 46XX, three copies of the PHEX gene being identified, except in exon 16, of which only two were detected. This finding, consistent with a deletion of that exon in one of the three copies, was also observed in the genetic study of the mother; this was therefore probably the cause of the disease. The fact that the patient presented X trisomy and that the deletion was in only one of the 3 copies could explain the scant clinical expressivity.

Since diagnosis, the patient has been treated with oral phosphorus and calcitriol, and although adherence proved erratic during adolescence, it is currently adequate. In these years she has developed secondary hyperparathyroidism and incipient nephrocalcinosis.

In conclusion, XLH is characterized by broad variability in its clinical expression, with no clear genotype-phenotype relationship, and management of the disease requires a multidisciplinary team of specialists. Moreover, it should be kept in mind that there are scantly symptomatic forms of the disease that are difficult to diagnose in the absence of affected relatives, particularly when they manifest in adulthood with chronic bone pain, fractures or pseudo-fractures, early osteoarthritis, dental problems, or enthesopathy.

Financial support

No funding has been received for the present study.

Conflicts of interest

The authors state that they have no conflicts of interest related to this paper.

S.S. Beck-Nielsen, B. Brock-Jacobsen, J. Gram, K. Brixen, T.K. Jensen.
Incidence and prevalence of nutritional and hereditary rickets in southern Denmark.
Eur J Endocrinol, 160 (2009), pp. 491-497
M.D. Ruppe.
X-Linked Hypophosphatemia.
J. Gattineni, C. Bates, K. Twombley, V. Dwarakanath, M.L. Robinson, R. Goetz, et al.
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
Am J Physiol Physiol, 297 (2009), pp. F282-91
V. Pavone, G. Testa, S. Gioitta Iachino, F.R. Evola, S. Avondo, G. Sessa.
Hypophosphatemic rickets: etiology, clinical features and treatment.
Eur J Orthop Surg Traumatol, 25 (2014), pp. 221-226
D. Chesher, M. Oddy, U. Darbar, P. Sayal, A. Casey, A. Ryan, et al.
Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations.
J Inherit Metab Dis, 41 (2018), pp. 865-876
T.O. Carpenter, E.A. Imel, I.A. Holm, S.M. Jan de Beur, K.L. Insogna.
A clinician’s guide to X-linked hypophosphatemia.
J Bone Miner Res, 26 (2011), pp. 1381-1388
M.P. Whyte, T.O. Carpenter, G.S. Gottesman, M. Mao, A. Skrinar, J. San Martin, et al.
Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Lancet Diabetes Endocrinol, 7 (2019), pp. 189-199
K.L. Insogna, K. Briot, E.A. Imel, P. Kamenický, M.D. Ruppe, A.A. Portale, et al.
A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis.
J Bone Miner Res, 33 (2018), pp. 1383-1393

Please cite this article as: Broseta JJ, López-Romero LC, Cerón JA, Mendizábal S, Hernández-Jaras J. Mosaicismo en 2 casos de hipofosfatemia ligada al cromosoma X. Endocrinol Diabetes Nutr. 2020;67:70–71.

Copyright © 2019. SEEN and SED
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.